作者: Linh N.K. Tran , Ganessan Kichenadasse , Pamela J. Sykes
DOI: 10.2174/1568009618666180724111604
关键词: Medicine 、 Cancer 、 Cancer research 、 Prostate cancer 、 PTEN 、 Androgen receptor 、 Fusion gene 、 Histone deacetylase inhibitor 、 Valproic Acid 、 Metformin
摘要: Prostate cancer (PCa) is the most frequent in men. The evolution from local PCa to castration-resistant PCa, an end-stage of disease, often associated with changes genes such as p53, androgen receptor, PTEN, and ETS gene fusion products. Evidence accumulating that repurposing metformin (MET) valproic acid (VPA) either when used alone, or combination, another therapy, could potentially play a role slowing down progression. This review provides overview application MET VPA, both alone combination other drugs for treatment, correlates responses these common molecular then describes potential combined VPA systemic therapy prostate cancer, based on interacting mechanisms.